J J J Smit

Publications (5)7.33 Total impact

• Article: Unusual twiddler syndrome: movement ties the knot.

  J Constandse, J J J Smit, A R Ramdat Misier, A Elvan, P P H M Delnoy
  Netherlands heart journal: monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 05/2011; · 1.44 Impact Factor
• Article: Characteristics of Sprint Fidelis lead failure.

  R J Beukema, A R Ramdat Misier, P P H M Delnoy, J J J Smit, A Elvan
  [show abstract] [hide abstract]
  ABSTRACT: Background. The Medtronic Sprint Fidelis ICD lead is prone to failure and the rate of failure seems to be increasing. The aim of this study was to investigate the rate of Sprint Fidelis lead failure, the characteristics, the mode of presentation and possible predictors of lead failure.Methods and Results. The rate, characteristics and presentation of Sprint Fidelis lead failure was assessed in this single-centre survey. 619 Sprint Fidelis ICD leads were implanted at our centre between December 2004 and August 2007. The mean follow-up was 32+/-10 (range 22-60) months; 35 patients (5.7%) required a lead re-implantation because of failure of the pace-sense conductor. Mean duration of lead survival was 23+/-12 (2-46) months and the rate of failure did not stabilise during follow-up. The mode of presentation was inappropriate shocks in 16 patients (45.7%), alarm alert in 12 patients (34.3%), and detection at routine follow-up in seven patients (20%). In 31 patients (89%), interrogation data revealed a sudden rise in impedance and/or frequent short VV intervals prior to lead failure and in five patients an isolated decrease of R wave (<2.5 mV). The interrogation data were not different from patients with shocks compared with patients without shocks. The interrogation data at routine follow-up in the first three months after implant were normal and stable.Conclusion. The rate of Sprint Fidelis lead failure reaches 5.7% at a mean follow-up duration of 32 months. The rate of failure does not seem to stabilise. Routine follow-up can not predict lead failure or prevent inappropriate shocks. (Neth Heart J 2010;18:12-7.).
  Netherlands heart journal: monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 01/2010; 18(1):12-7. · 1.44 Impact Factor
• Source

  Available from: Jan Paul Ottervanger

  Article: Iron-induced platelet aggregation measurement: a novel method to measure platelet function in stenting for ST segment elevation myocardial infarction.

  J J J Smit, W van Oeveren, J P Ottervanger, R J Slingerland, J A Remijn, F Zijlstra, A W J van 't Hof
  [show abstract] [hide abstract]
  ABSTRACT: Iron and (stainless) steel are potent platelet aggregation activators, and may be involved in stent thrombosis, a serious complication after intracoronary stenting. Current platelet function tests are suboptimal, because of inappropriate agonists and/or lack of reproducibility. We tested the feasibility and reproducibility of a novel platelet function test using stainless steel as an agonist and compared it with other platelet function tests. In 111 patients with acute ST segment elevation myocardial infarction (STEMI), duplo measurements of iron (Fe)-induced platelet aggregation (FIPA) were performed after clopidogrel, acetylsalicylic acid and/or tirofiban treatment. Within 1 h, citrated blood samples drawn from the femoral sheath before primary percutaneous coronary intervention were added to 100 mg of low carbon steel and after 5 s mixing with vortex, the samples were incubated for 15 min. The ratio between the non-aggregated platelets in the agonist sample and platelets in a reference sample was calculated as the platelet aggregation inhibition. FIPA measurement was highly reproducible (correlation coefficient (R)=0.942, P<0.001 between duplo samples). FIPA correlated well with adenosine diphosphate-induced platelet aggregation (R=0.83, P<0.001) but weakly with platelet function analyser-100 bleeding time (R=0.56, P<0.001). FIPA could be measured in patients in which platelet aggregation could not be measured by platelet function analyser-100 or after adenosine diphosphate. This study showed good reproducibility of a novel platelet function test using stainless steel as an agonist and showed correlation with validated platelet function tests. We found that the novel platelet function test is a suitable test for measurement of platelet aggregation inhibition in patients undergoing stenting for STEMI, even when they are taking multiple antiplatelet regimens.
  European Journal of Clinical Investigation 02/2009; 39(2):103-9. · 3.02 Impact Factor
• Article: Does glycoprotein IIB/IIIA resistance exist?

  J J J Smit, A W J van 't Hof
  [show abstract] [hide abstract]
  ABSTRACT: Platelet function testing is not embedded into routine clinical practice, because no optimal, easy, reproducible and multipathway platelet aggregation test can be accomplished in vitro. Only recently, the relationship between the level of platelet aggregation inhibition by platelet inhibitors and clinical outcome in acute myocardial infarction became more clear.1-5 High platelet reactivity was found in patients who experienced stent thrombosis, and patients with clopidogrel resistance were at increased risk of recurrent atherothrombotic events.1,2 Furthermore, in ST-elevation myocardial infarction (STEMI) increased levels of platelet aggregation were found compared with unstable angina or control patients.4 In a thrombolysis study, higher platelet receptor occupancy was coupled with better angiographic and electrocardiographic outcome.
  Netherlands heart journal: monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 12/2007; 15(11):367-8. · 1.44 Impact Factor
• Source

  Available from: nih.gov

  Article: Impaired platelet inhibitory effect of a single dose of acetylsalicylic acid in patients with unstable coronary artery syndrome in comparison with healthy volunteers

  J J J Smit, J C A Hoorntje, K Miedema, W. van Oeveren